NYKD Share Price Performance
NOK 4.04
2.55 (171.14%)
35.4% undervalued intrinsic discount
NOK 6.25
Fair Value
Price NOK 4.04
AnalystConsensusTarget NOK 6.25
Fair ValueNOK 6.25
Share Pricen/a
Narrative Update • Sep 03
Nykode Therapeutics AS Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
NYKD Community Narratives
AN
Fair Value
·Fair Value NOK 6.25 35.4% undervalued intrinsic discount
Head And Neck Cancer Trial Progress And Cash Runway Will Support Long Term Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Nykode Therapeutics
35.4% undervalued intrinsic discount
Head And Neck Cancer Trial Progress And Cash Runway Will Support Long Term Potential
View narrativeAN
Updated 3 Sep
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
NYKD: Neoantigen Platform Progress Will Support Higher Long-Term Earnings Multiple
Fair Value: NOK 6.25 35.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nykode Therapeutics AS Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 25, 2026
- -0.07
- 100.00%
- -4,946.77%
- 0%
About NYKD
- Founded
- 2006
- Employees
- 59
- CEO
- WebsiteView website
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
